Tissue Regenix Group (FRA:LSW) Net Income From Continuing Operations: €-9.88 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LSW Tissue Regenix Group PLC FRA:LSW
10 GF Score
Price €0.07
GF Value €0.84
! 7 Warning Signs
View Full Analysis

What is Tissue Regenix Group Net Income From Continuing Operations?

Tissue Regenix Group FRA:LSW 10 Net Income From Continuing Operations is €-9.88 Mil as of Dec. 2025. GuruFocus rates FRA:LSW with a GF Score™ of 10/100 and a GF Value™ of €0.84. The stock has 7 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Tissue Regenix Group's net income from continuing operations for the six months ended in Dec. 2025 was €-9.04 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-9.88 Mil.

Tissue Regenix Group Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group Net Income From Continuing Operations Chart

Tissue Regenix Group Annual Data
Trend Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.55 -2.67 -1.53 -1.93 -9.87

Tissue Regenix Group Semi-Annual Data
Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.69 0.12 -2.06 -0.84 -9.04
FRA:LSW
10GF Score
Tissue Regenix Group PLC FRA:LSW
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tissue Regenix Group Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-9.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of €-9.88 Mil mean?
Tissue Regenix Group (FRA:LSW) has a Net Income From Continuing Operations of €-9.88 Mil as of Dec. 2025. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Net Income From Continuing Operations too high?
Tissue Regenix Group's current Net Income From Continuing Operations is €-9.88 Mil. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Net Income From Continuing Operations compare to VRTX and REGN?
Tissue Regenix Group's Net Income From Continuing Operations of €-9.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Tissue Regenix Group and its competitors. Tissue Regenix Group's current Net Income From Continuing Operations is €-9.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Net Income From Continuing Operations of €-9.88 Mil. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Net Income From Continuing Operations is €-9.88 Mil. Tissue Regenix Group's overall GF Score™ is 10/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Net Income From Continuing Operations is €-9.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?

Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued. The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.

Key valuation signals for FRA:LSW:

  • Net Income From Continuing Operations: €-9.88 Mil
  • GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
  • GF Score™: 10/100 with 7 warning signs

No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score

Get the complete analysis for FRA:LSW

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.84
GF Value